The Biggest Overhaul in Decades: What Is a Bio Mega Special Zone?
Korea's Regulatory Free Zone system is undergoing its most significant redesign since introduction, and the centerpiece is the new "Mega Special Zone." Where conventional regulatory free zones granted exemptions on a project-by-project basis for two years (extendable to four), a Mega Special Zone operates at the metropolitan level — broader exemption scope, longer duration, and direct linkage to government R&D and fund investment. The character of the program shifts from a temporary sandbox for testing rules to a full investment package for building an industry.
In 2026, seven new regulatory free zones were designated, including Gyeongnam, Gyeongbuk, Ulsan, and Jeonbuk, with bio and medical fields accounting for a substantial share. Combined with a 1 trillion won mega fund and expanded regional healthcare R&D, this creates a rare window in which regulatory relief, capital, and demand open simultaneously for bio companies based outside the capital region.
The Core Change: "Menu-Style" Regulatory Exemptions
The most practically significant shift is the menu-style exemption model. Instead of companies fitting their business into government-defined projects, local governments and companies select the exemptions they need from a pre-organized list and apply for them.
Running this in parallel with the existing regulatory sandbox (demonstration exemption / temporary authorization) is possible, but filing the same regulatory issue on two tracks duplicates ministry review and delays both. A practical division: use the special zone for regionally anchored, multi-company initiatives, and the sandbox for a single company's one-off demonstration.
The Opportunity in Decentralized Clinical Trials (DCT)
For the bio sector, the highest-impact item is the decentralized clinical trial (DCT) exemption. Limited to trials using already-approved drugs, it recognizes as valid clinical procedure the practice of participants self-administering at home and transmitting dosing records and wearable-device measurements.
An exemption, however, is conditional permission — not a waiver. Approval requires documented procedures for electronic consent (eConsent), data integrity (ALCOA+) for self-administration records, remote monitoring SOPs, adverse-event response protocols, and temperature-controlled drug shipping and storage.
Participation Strategy for Small and Mid-Sized Bio Companies
Checklist and Common Reasons for Rejection
How KITIM Supports You
KITIM supports bio and medical companies with regulatory diagnosis to pinpoint the exact provisions blocking your business, drafting menu-style exemption applications and safety management plans, designing SOPs and data governance for DCT adoption, and identifying linked projects under the mega fund and regional R&D programs. If you are weighing participation in a special zone or struggling to structure your application, contact KITIM. We will assess your technology and regulatory constraints together and propose the most viable route to participation.